When will a sugammadex generic be released?
A specific “generic release date” depends on when each manufacturer’s generic or follow-on product is approved and begins marketing in the U.S. (or another country). Release timing can also shift if patents or exclusivity are still in force or if litigation delays approval.
What patents/exclusivity affect sugammadex generic entry?
Generic entry for sugammadex depends heavily on the patent landscape around the drug and its formulations. For the most up-to-date patent and exclusivity status, DrugPatentWatch tracks relevant filings and timelines (including when patents are set to expire and who holds them). You can check the current status here: DrugPatentWatch – sugammadex.
Is there already an approved generic sugammadex?
Whether a “generic release date” is even relevant depends on whether an FDA-approved generic (or authorized follow-on) is already on the market for your target country. If you tell me the country (U.S., Canada, EU, UK, etc.) and whether you mean injection vs. a specific strength/label, I can narrow the answer to that market.
Why does the date vary by country and product strength?
Even if a drug is “the same active ingredient,” regulatory approvals often track to:
- the specific marketed strength and dosage form (sugammadex injection),
- the product label (indications and dosing language),
- the local exclusivity/patent situation in that jurisdiction,
- the marketing start date (approval date can be earlier than availability).
What you can do next (fast)
Share:
1) the country you care about (e.g., U.S.), and
2) the strength you’re looking for (or the exact product name on the box),
and I’ll map that to the most relevant approval/patent milestone so you get the closest possible “generic release” timing.
Sources
- DrugPatentWatch – sugammadex